Investment

  Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders, complementing and strengthening the Group’s growing nephrology portfolio Sanifit’s lead compound, SNF472 is a novel, first-in-class inhibitor of vascular calcification in phase 3, developed for the treatment of calcific uremic arteriolopathy (CUA) and peripheral artery disease (PAD) in patients with end-stage kidney disease Purchase price includes an upfront payment of EUR…

Industry veteran in oncology antibody discovery & development Dr Haijun Sun appointed Chief Scientific Officer Expansion of the Scientific Advisory Board with appointments of leading experts in preclinical, translational and clinical drug development Barcelona, Spain, 21 October 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism in order to treat advanced cancer, announces today the appointment of Dr Haijun Sun as…

Barcelona October 4th, 2021. Mediktor – the Spanish healthtech company which provides a sophisticated pre-diagnosis medical assistant – announced that it has raised a €11 million financing round to keep on improving their elaborate technology and expand their international presence. The round was led by European healthtech growth capital investor MTIP. Existing investor Alta Life Sciences participated as well. Mediktor has developed a medical assistant that is based on Artificial…

Diagnostics industry veteran with forty years’ experience to support DeepUll in its continued development of its early sepsis identification system BARCELONA, Spain – October 4 2021 – DeepUll, a medical diagnostics company developing culture-free, affordable diagnostic solutions for the early identification of sepsis and other acute infections, announces today that it has appointed Richard (“Rick”) Ivey as a non-executive director. With four decades of senior leadership experience in the diagnostics…

• Level 1 evidence from the MAF Test ®analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test ® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis. • Data published in Journal of National Cancer Institute, Cancer Spectrum. • MAF negative status of patients who were treated with clodronate in the adjuvant setting was predictive of significantly improved…

Article By: Graphene Flagship Graphene Flagship Publishing date: 08 July 202 https://graphene-flagship.eu/graphene/news/graphene-flagship-spin-off-inbrain-signs-collaboration-with-merck-to-develop-next-generation-bioelectronics/

https://sifted.eu/articles/spain-startups-top-ranking/

https://mybinxhealth.com/news/binx-health-raises-104-million-in-series-e-financing/

https://mybinxhealth.com/news/binx-health-submits-request-for-emergency-use-authorization-for-first-crispr-based-point-of-care-test-for-covid-19/

Barcelona, Thursday 6th May 2021 Peptomyc, a Spanish clinical stage biotech company spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA) in Barcelona, reported that on Tuesday 4th May the first patient has been dosed with OMO-103, its anti-MYC lead compound, in a Phase I/II study, under the supervision of Dr. Elena Garralda at the Hospital Universitari Vall d’Hebron in…